Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Targovax announces poster at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oslo, Norway, 9 November 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces that the poster “A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12-month analysis of biomarkers and clinical outcomes” are now available at the Company’s website.The abstract presents the 12-month analysis of biomarkers and clinical outcome from the phase I/II trial in malignant pleural mesothelioma where ONCOS-102

Neste Corporation - Managers' Transactions, Nyberg (disposal)

Neste Corporation, Managers' Transactions, 9 November 2020 at 5.30 p.m. (EET)____________________________________________Person subject to the notification requirementName: Nyberg, CarlPosition: Other senior managerIssuer: Neste OyjLEI: 5493009GY1X8GQ66AM14Notification type: INITIAL NOTIFICATIONReference number: 5493009GY1X8GQ66AM14_20201109170401_4____________________________________________Transaction date: 2020-11-09Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009013296Nature of the transaction: DISPOSALTransaction details(1): Volume:

Peptonic to exercise loan option of 7.5 MSEK with Vidarstiftelsen

Stockholm, November 9, 2020 – Peptonic Medical AB (publ) (“Peptonic” or the “Company”) today announced that it has exercised the option to obtain a loan of 7.5 MSEK from Vidarstiftelsen according to an agreement as signed in May 2020.According to the terms of the loan agreement, the loan shall be paid out upon the Company’s request during the period 1 November 2020 to 28 February 2021. The loan is subject to an annual interest of 7 percent, to be paid in cash on a monthly basis. The loan can be converted to shares in Peptonic upon request by either of Peptonic or Vidarstiftelsen at fixed

#20-400 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

Peptonic Medical files patent application for the treatment of fungal infections and bacterial vaginosis

Stockholm, November 9[th], 2020 - Peptonic Medical AB (publ) (‘Peptonic’ or ‘Company’) announces today that the Company has submitted an application for patent protection for the treatment of genital fungal infections and bacterial vaginosis with a modified VagiVital® formulation. The background to this application is i.a. positive results from in vitro studies showing an effective antifungal effect. Women suffering from fungal infections have spontaneously used VagiVital® and reported good results. In the new formulation, the properties that are judged to contribute to the positive treatment

BioStock: Xintela's CEO comments on the positive patent notice

Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases. At the end of October, Xintela announced that the European Patent Office (EPO) has issued an ”Intention to grant” for the patent application covering the company’s stem cell product XSTEM. Once the patent is approved, the stem cell product will be protected on the European market for at least another 18 years. BioStock has contacted Evy Lundgren-Åkerlund, CEO of Xintela, to find out more about XSTEM and the patent.Read the full article at biostock.se:

EAB Group Plc: Schedule for financial reporting in 2021

EAB Group Plc, Stock Exchange Release, 9 November 2020, 5:00 p.m. (EET) EAB Group Plc: Schedule for financial reporting in 2021 In 2021 EAB Group Plc will publish the following financial releases: · Financial statements bulletin 2020 will be published on Friday 12 February 2021. · Annual Report 2020 will be published on Thursday 4 March 2021. · Half-year financial report January–June 2021 will be published on Friday 6 August 2021. The financial releases will be published in Finnish and English. The financial bulletins and reports can also be read in Finnish at EAB Group’

Fortum's Capital Markets Day 2020

FORTUM CORPORATION INVESTOR NEWS 9 NOVEMBER AT 16:45 EET Fortum will arrange a virtual Capital Markets Day as a webcast for institutional investors and analysts on 3 December 2020 at 13.00–16.30 EET. Following the strategy alignment between Fortum and Uniper during this autumn, the CMD programme will focus on Fortum Group’s strategy and will include presentations by Fortum’s President and CEO Markus Rauramo and acting CFO Timo Karttinen, as well as Uniper’s CEO Andreas Schierenbeck. The link to the live webcast and the detailed agenda for the event is published on Fortum's CMD 2020

New research to protect public from violent extremists

The Counter Extremism Project (CEP) and Staffordshire University are joining forces on a ground-breaking research project which aims to shed new light on the intentions of violent extremists.The ‘Disguised compliance in terrorist offending’ project will provide frontline staff across UK security agencies with the best tools and approaches to assess the true intentions of people motivated to acts of violence by ideologies. The research finding will be valuable to those who interrogate suspects and gather intelligence. The project, led on behalf of CEP by international extremism expert

Anders Tidfors new CFO of WntResearch

Anders Tidfors has a strong background including several CFO assignments, both nationally and internationally. With considerable experience from leading financial roles, Tidfors will strengthen WntResearch in executing the Company's clinical programs with the drug candidate Foxy-5. Tidfors will take up appointment in mid-November, initially combining part-time work for WntResearch with other assignments, including work for a listed company."I look forward to continue to develop WntResearch's organization, financial control and positioning together with Anders to implement the company's

Acroud signs LOI to acquire the PMG Group to solidify their strategic position as “the Media House of the Future”

Acroud AB (publ) (“Acroud”) has signed another Letter of Intent (“LOI”) regarding the acquisition of the iGaming assets of PMG Group (“PMG”). PMG is a fast-growing company active within predominately the European market with the affiliate network Matching Visions and the iGaming campaign broker Traffic Grid, but is also an industry leading SaaS service provider with Voonix. This is the latest out of three LOIs that Acroud recently has signed as part of the strategy to create “the Media House of the Future” and become a fast-growing global challenger in digital comparison and news services.

Nel ASA: Receives purchase orders for U.S. Navy PEM electrolyser stacks

(Oslo, 09 November, 2020) Nel Hydrogen U.S., the U.S. subsidiary of Nel ASA (Nel, OSE:NEL), has received purchase orders for PEM electrolyser cell stacks from Raytheon Technologies´ Collins Aerospace Division, at a combined value of more than USD 5.4 million. Nel’s electrolyser stacks produce critical life support oxygen for U.S. Navy crews on multiple classes of nuclear-powered submarines and are being delivered under an exclusive contract. “We are very proud to work with our partner Collins Aerospace and the U.S. Navy on this mission critical application for PEM electrolysis. This new

One step closer to 2025 targets: UPM Raflatac announces progress towards Ellen MacArthur Foundation and UNEP’s New Plastics Economy Global Commitment

(UPM Raflatac, Helsinki, 9 November 2020 at 16:00 EET) – Global pressure sensitive label material supplier UPM Raflatac is pleased to announce it has made great progress toward a more circular economy for plastics and a future beyond fossils. This progress is detailed in the New Plastics Economy Global Commitment 2020 Progress Report by the Ellen MacArthur Foundation and the UN Environment Programme. UPM Raflatac is the only pressure sensitive labeling company to have announced targets for reducing unnecessary plastic packaging as a signatory of the Global Commitment. As highlighted in

Tuska Utopia combines a travel show with metal music – a brand new way to experience Finland

While music and travel industries are suffering from the lockdown and people around the globe have fewer opportunities to enjoy concerts and fulfil their wanderlust, Tuska Utopia offers a new way of experiencing both of these. The concept sees Finnish artists performing and audiences embarking on a journey to intriguing landscapes in the global home of heavy metal, from church ruins to disused gasometers. Combining an entertaining travel show, one-of-a-kind metal concerts and state-of-the-art music video aesthetics, Tuska Utopia  will receive its

Repurchase of shares in Intrum AB (publ)

During the period 2 November 2020 until 6 November 2020, Intrum AB (publ) (“Intrum”) has repurchased a total of 125,000 shares as part of the buyback program introduced by the Board of Directors to secure the obligations of Intrum (including social security contributions) relating to the long-term incentive program 2020. As a result, the buyback program, which Intrum announced on 23 October 2020, is hereby completed since the maximum amount of shares (250,000) has been repurchased. The buyback program was carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”)

Mandatory notification of trade – primary insider

The following primary insider in Multiconsult ASA has sold shares in Multiconsult ASA: Torben Halland Wedervang, deputy board member (employee representative) Multiconsult ASA, has on 9 November 2020 sold 1 000 shares in Multiconsult ASA at an average price of NOK 121.00 per share and will after the transaction hold 2 314 shares in Multiconsult ASA.For further information, please contact:    Investor relations:      Pål-Sverre Jørgensen, Group Treasurer & Investor Relations Officer      Phone: +47 416 11 161      E-mail: ir@multiconsult.no    Media:      Gaute Christensen, VP

First patient enrolled in the phase I/II clinical trial testing FG001 in patients with high grade glioma

Copenhagen, Denmark, 9 November 2020 - FluoGuide A/S (“FluoGuide” or “the Company”) is pleased to inform that the first patient today was enrolled in the clinical trial testing safety and efficacy of FG001 in guiding high grade glioma surgery.FluoGuide’s phase I/II clinical trial, testing FG001 in patients with high grade glioma consists of two phases; (1) a dose escalation phase to establish safety and proof-of-concept, and (2) an efficacy assessment phase. The total number of patients in the entire phase I/II trial will be up to 36 patients. FluoGuide is pleased to inform that the

Mandatory notification of trade – primary insider

The following primary insider in Multiconsult ASA has purchased shares in Multiconsult ASA: Grethe Bergly, CEO in Multiconsult ASA,has on 9 November 2020 purchased 1 000 shares in Multiconsult ASA at an average price of NOK 123.00 per share and will after the transaction hold 29 751 shares in Multiconsult ASA.For further information, please contact:    Investor relations:      Pål-Sverre Jørgensen, Group Treasurer & Investor Relations Officer      Phone: +47 416 11 161      E-mail: ir@multiconsult.no    Media:      Gaute Christensen, VP Communications      Phone: +47 911

Rabbalshede Kraft publishes EU-growth prospectus

The Board of Rabbalshede Kraft AB (publ) has prepared an EU growth prospectus regarding the forthcoming rights issue of the company's B shares. The prospectus has today, November 9, 2020, been approved and registered by the Swedish Financial Supervisory Authority.On November 5 2020, the Board of Rabbalshede Kraft claimed the authorization decided by the annual general meeting on April 28 2020, and decided that the company’s share capital shall increase by a maximum of SEK 142 298 795 through a new issue of a maximum of 28 459 759 Series B shares in the company. The Board’s decision is in

Brighter has qualified to the top 10 in the Healthtech Unicorn Battle Europe

Brighter was nominated to the Healthtech Unicorn Battle Europe and, as a result, has qualified as one of the carefully selected top rated companies that are given the opportunity to pitch their idea live in the contest. The submission relates primarily to Brighter’s pioneering diabetes offering, Actiste® Diabetes Management as a Service. “We are very proud to be one of the few selected companies. It confirms that Brighter is on the right track with our aim and mission, and we are ready to make an impact,” says Henrik Norström, CEO Brighter. Date and time: November 10, 2020, 3 pm CET.

Exercise of Mandatory Exchange Option

International Personal Finance plc (IPF) specialises in providing unsecured consumer credit to 1.7 million customers across 10 markets. IPF operates the world's largest home credit business and a successful fintech business, IPF Digital. INTERNATIONAL PERSONAL FINANCE PLC ANNOUNCES EXERCISE OF MANDATORY EXCHANGE OPTION INTERNATIONAL PERSONAL FINANCE PLC (incorporated with limited liability in England and Wales with registered number 06018973)(the "Issuer" or "IPF") EUR 412,000,000 5.75 per cent. Senior Unsecured Unsubordinated Fixed Rate Notes due 2021 (ISIN: XS1054714248) (

Alligator Bioscience presents at the SITC 35th Annual Meeting

Three projects showcased   -  ATOR-1015, ALG.APV-527 and Neo-X-Prime  -Lund, Sweden, November 9, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it will present data from three immuno-oncology projects at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting, November 9-14, 2020. The presentations will include the Phase I study of ATOR-1015, the Phase I-ready ALG.APV-527 developed in partnership with Aptevo Therapeutics, as well as the novel bispecific concept Neo-X-Prime. “The fact that three of our immuno-oncology projects have

Arcus ASA: Supplement to the prospectus prepared for the merger of Altia Plc and Arcus ASA

THIS STOCK EXCHANGE RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE COMPLETED OR REGISTERED OR REQUIRE ANY MEASURE TO BE UNDERTAKEN IN ADDITION TO THE REQUIREMENTS UNDER FINNISH LAW. FOR FURTHER INFORMATION, SEE “IMPORTANT NOTICE” BELOW.The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the

The Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the merger of Altia Plc and Arcus ASA

ALTIA PLC  STOCK EXCHANGE RELEASE  9 NOVEMBER 2020 AT 3:00 p.m. EET THIS STOCK EXCHANGE RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR RULES OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE COMPLETED OR REGISTERED OR REQUIRE ANY MEASURE TO BE UNDERTAKEN IN ADDITION TO THE REQUIREMENTS UNDER FINNISH LAW. FOR FURTHER INFORMATION, SEE “IMPORTANT NOTICE” BELOW. The Finnish Financial Supervisory

There are no items matching the current filter
There are no more items matching the current filter
Back to top